"Androstadienes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of the steroid androstane having two double bonds at any site in any of the rings.
| Descriptor ID |
D000730
|
| MeSH Number(s) |
D04.210.500.054.079.129
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Androstadienes".
Below are MeSH descriptors whose meaning is more specific than "Androstadienes".
This graph shows the total number of publications written about "Androstadienes" by people in this website by year, and whether "Androstadienes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2000 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2007 | 1 | 2 | 3 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Androstadienes" by people in Profiles.
-
Diaby V, Adunlin G, Ali AA, Tawk R. Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat. 2014 Aug; 146(3):669-73.
-
Diaby V, Adunlin G, Zeichner SB, Avancha K, Lopes G, Gluck S, Montero AJ. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Sep; 147(2):433-41.
-
McQuaid EL, Fedele DA, Adams SK, Koinis-Mitchell D, Mitchell J, Kopel SJ, Seifer R, Jandasek B, Fritz GK, Canino G. Complementary and alternative medicine use and adherence to asthma medications among Latino and non-Latino white families. Acad Pediatr. 2014 Mar-Apr; 14(2):192-9.
-
Soifer HS, Souleimanian N, Wu S, Voskresenskiy AM, Collak FK, Cinar B, Stein CA. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem. 2012 Feb 03; 287(6):3777-87.
-
Tiwary R, Yu W, Sanders BG, Kline K. a-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways. Br J Cancer. 2011 Jan 04; 104(1):101-9.
-
Xiong Y, Zhou Y, Jarrett HW. Dystrophin glycoprotein complex-associated Gbetagamma subunits activate phosphatidylinositol-3-kinase/Akt signaling in skeletal muscle in a laminin-dependent manner. J Cell Physiol. 2009 May; 219(2):402-14.
-
Sugawara T, Ayer R, Jadhav V, Chen W, Tsubokawa T, Zhang JH. Simvastatin attenuation of cerebral vasospasm after subarachnoid hemorrhage in rats via increased phosphorylation of Akt and endothelial nitric oxide synthase. J Neurosci Res. 2008 Dec; 86(16):3635-43.
-
Nyan DC, Anbazhagan R, Hughes-Darden CA, Wachira SJ. Endosomal colocalization of melanocortin-3 receptor and beta-arrestins in CAD cells with altered modification of AKT/PKB. Neuropeptides. 2008 Jun; 42(3):355-66.
-
Otero M, Lago R, G?mez R, Lago F, Gomez-Reino JJ, Gualillo O. Phosphatidylinositol 3-kinase, MEK-1 and p38 mediate leptin/interferon-gamma synergistic NOS type II induction in chondrocytes. Life Sci. 2007 Oct 27; 81(19-20):1452-60.
-
Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax. 2007 Nov; 62(11):938-43.